Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

BioArctic

Tracked across 15 events · 114 articles · First seen Apr 21, 2026 · Last active Sep 22, 2026

Sentiment
29
Attention
4
Events
15
Relationships
6
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Business
Impact: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
May 28, 2026 · 9 articles
1 0
Business
Impact: BioArctic issued 5,000 Class B shares to participants in its stock option program, increasing its total number of shares and votes.
May 29, 2026 · 6 articles
2 60
Business
Impact: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Jul 29, 2026 · 6 articles
0 0
Business
Impact: BioArctic is the company issuing the Q2 report and hosting the investor presentation. The event is routine and does not change its outlook.
Aug 19, 2026 · 6 articles
2 20
Business
Impact: BioArctic is a key party, contributing its BrainTransporter technology and leading drug candidate generation. The collaboration expands its pipeline into oncology, potentially enhancing its growth prospects.
Aug 19, 2026 · 6 articles
0 0
Business
Impact: BioArctic issued 20,200 Class B shares under its stock option program, increasing its total share count to 88,744,685. This routine action has no significant impact on the company's valuation or operations.
Aug 31, 2026 · 8 articles
4 80
Regulatory
Impact: BioArctic is the inventor of Leqembi and receives royalties on global sales. The Canadian reimbursement recommendation is a positive development that could increase future revenue.
Sep 01, 2026 · 6 articles
2 30
Tech
BioArctic announced that Leqembi (lecanemab), the first therapy targeting an underlying cause of Alzheimer's disease, is now available at a private clinic in Sweden and that the first patient has started treatment. This marks the…
Impact: BioArctic is the central actor, announcing the first Swedish patient treated with Leqembi and holding Nordic commercialization rights with Eisai. The launch supports its royalty and milestone revenue stream, though the negative NT-radet reimbursement recommendation limits near-term Swedish sales.
Sep 22, 2026 · 7 articles
4 70
Business
Impact: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
4 70
Business
Impact: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.
May 25, 2026 · 7 articles
4 80
Business
Impact: Inventor of lecanemab; entitled to royalties and sales milestones from Eisai. The US launch of Leqembi Iqlik strengthens its commercial prospects.
Aug 24, 2026 · 6 articles
2 10
Tech
Impact: Greta Duréel has consulted for BioArctic, but no direct impact from this study.
Aug 12, 2026 · 14 articles
2 0
Business
May 13, 2026 · 7 articles
4 0
Regulatory
May 08, 2026 · 14 articles
2 0
Business
Apr 21, 2026 · 6 articles
Eisai licensor ↔ BioArctic BioArctic is a research-based biopharma company that licenses its proprietary te
Eisai licensee ↔ BioArctic Eisai is a global pharmaceutical company that licenses proprietary technologies
Lars Lannfelt ↔ BioArctic
Lars Lannfelt ↔ BioArctic
Biogen ↔ BioArctic
Biogen ↔ BioArctic
ERGEN INTELLIGENCE
Track BioArctic live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.